In vivo TLR9 inhibition attenuates CpG-induced myocardial dysfunction

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Boehm, O ^a   Markowski, P ^a   Van Der Giet, M ^a   Gielen, V ^a   Kokalova, A ^a   Brill, C ^a   Hoeft, A ^a   Baumgarten, G ^a   Meyer, R ^b   Knuefermann, P ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICALS AND DRUGS; CHLOROQUINE; CPG OLIGODEOXYNUCLEOTIDE; H 154 THIOATE; IRS 954 THIOATE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; OLIGODEOXYRIBONUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HEART PROTECTION; HEMODYNAMICS; IN VIVO STUDY; MALE; MORTALITY; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SURVIVAL; ANIMAL; C57BL MOUSE; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; HEART; HEART MUSCLE; METABOLISM; PATHOLOGY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; TOXICITY;

ANIMALS; CELL LINE; CHLOROQUINE; HEART; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877301394     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/217297     Document Type: Article

References (33)

1. Mohan C., Zhu J., Toll-like receptor signaling pathways-therapeutic opportunities. Mediators of Inflammation 2010 2010 2-s2.0-78349255916 10.1155/2010/781235 781235
2. Seeley E. J., Matthay M. A., Wolters P. J., Inflection points in sepsis biology: from local defense to systemic organ injury. American Journal of Physiology 2012 303 5 L355 L363
3. Ehrentraut S. F., Dorr A., Ehrentraut H., Lohner R., Lee S. H., Hoeft A., Baumgarten G., Knuefermann P., Boehm O., Meyer R., Vascular dysfunction following polymicrobial sepsis: role of pattern recognition receptors. PloS One 2012 7 9 e44531
4. Plitas G., Burt B. M., Nguyen H. M., Bamboat Z. M., DeMatteo R. P., Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis. Journal of Experimental Medicine 2008 205 6 1277 1283 2-s2.0-45149129895 10.1084/jem.20080162 (Pubitemid 351831485)
5. Parrillo J. E., Parker M. M., Natanson C., Suffredini A. F., Danner R. L., Cunnion R. E., Ognibene F. P., Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Annals of Internal Medicine 1990 113 3 227 242 2-s2.0-0025303027 (Pubitemid 20242299)
6. Zanotti-Cavazzonia S. L., Hollenberg S. M., Cardiac dysfunction in severe sepsis and septic shock. Current Opinion in Critical Care 2009 15 5 392 397 2-s2.0-70350123038 10.1097/MCC.0b013e3283307a4e
7. Knuefermann P., Schwederski M., Velten M., Krings P., Ehrentraut H., Rüdiger M., Boehm O., Fink K., Dreiner U., Grohé C., Hoeft A., Baumgarten G., Koch A., Zacharowski K., Meyer R., Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of Toll-like receptor 9. Cardiovascular Research 2008 78 1 26 35 2-s2.0-41149145130 10.1093/cvr/cvn011 (Pubitemid 351430962)
8. Hong Z., Jiang Z., Liangxi W., Guofu D., Ping L., Yongling L., Wendong P., Minghai W., Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. International Immunopharmacology 2004 4 2 223 234 2-s2.0-1542302690 10.1016/j.intimp.2003.12.006 (Pubitemid 38296351)
9. Yamada H., Ishii K. J., Klinman D. M., Suppressive oligodeoxynucleotides inhibit CpG-induced inflammation of the mouse lung. Critical Care Medicine 2004 32 10 2045 2049 2-s2.0-5644227315 10.1097/01.CCM.0000142397.38134.EF (Pubitemid 39372538)
10. Barrat F. J., Meeker T., Gregorio J., Chan J. H., Uematsu S., Akira S., Chang B., Duramad O., Coffman R. L., Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. Journal of Experimental Medicine 2005 202 8 1131 1139 2-s2.0-26844467349 10.1084/jem.20050914 (Pubitemid 41464506)
11. Sparwasser T., Miethke T., Lipford G., Borschert K., Häcker H., Heeg K., Wagner H., Bacterial DNA causes septic shock. Nature 1997 386 6623 336 337 2-s2.0-0030897625 10.1038/386336a0 (Pubitemid 27154466)
12. Peter M., Bode K., Lipford G. B., Eberle F., Heeg K., Dalpke A. H., Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology 2008 123 1 118 128 2-s2.0-37149024435 10.1111/j.1365-2567.2007.02718.x (Pubitemid 350256002)
13. Velten M., Duerr G. D., Pessies T., Schild J., Lohner R., Mersmann J., Dewald O., Zacharowski K., Klaschik S., Hilbert T., Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice. Cardiovascular Research 2012 96 3 422 432 10.1093/cvr/cvs280
14. Knuefermann P., Baumgarten G., Koch A., Schwederski M., Velten M., Ehrentraut H., Mersmann J., Meyer R., Hoeft A., Zacharowski K., Groheandacute; C., CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo. Respiratory Research 2007 8 72 2-s2.0-38149111972 10.1186/1465-9921-8-72
15. Pacher P., Nagayama T., Mukhopadhyay P., Bátkai S., Kass D. A., Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nature Protocols 2008 3 9 1422 1434 2-s2.0-51649116447 10.1038/nprot.2008.138
16. Ehrentraut H., Meyer R., Schwederski M., Systemically administered ligands of toll-like receptor 2, -4, and -9 induce distinct inflammatory responses in the murine lung. Mediators of Inflammation 2011 2011 2-s2.0-79959243339 10.1155/2011/746532 746532
17. Sparwasser T., Miethke T., Lipford G., Erdmann A., Häcker H., Heeg K., Wagner H., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor- α -mediated shock. European Journal of Immunology 1997 27 7 1671 1679 2-s2.0-0030816325 10.1002/eji.1830270712 (Pubitemid 27302848)
18. Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., Klinman D. M., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995 374 6522 546 549 2-s2.0-0028931102
19. Kužnik A., Benčina M., Švajger U., Jeras M., Rozman B., Jerala R., Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. Journal of Immunology 2011 186 8 4794 4804 2-s2.0-79955046267 10.4049/jimmunol.1000702
20. Yasuda H., Leelahavanichkul A., Tsunoda S., Dear J. W., Takahashi Y., Ito S., Hu X., Zhou H., Doi K., Childs R., Klinman D. M., Yuen P. S. T., Star R. A., Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. American Journal of Physiology 2008 294 5 F1050 F1058 2-s2.0-45149116776 10.1152/ajprenal.00461.2007
21. Pawar R. D., Ramanjaneyulu A., Kulkarni O. P., Lech M., Segerer S., Anders H. J., Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. Journal of the American Society of Nephrology 2007 18 6 1721 1731 2-s2.0-34249915031 10.1681/ASN.2006101162 (Pubitemid 46870309)
22. Zeuner R. A., Ishii K. J., Lizak M. J., Gursel I., Yamada H., Klinman D. M., Verthelyi D., Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis and Rheumatism 2002 46 8 2219 2224 2-s2.0-0036674998 10.1002/art.10423
23. Halpern M. D., Pisetsky D. S., In vitro inhibition of murine IFN γ production by phosphorothioate deoxyguanosine oligomers. Immunopharmacology 1995 29 1 47 52 2-s2.0-0028832030 10.1016/0162-3109(95)00043-S
24. Pisetsky D. S., Reich C. F., Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. Clinical Immunology 2000 96 3 198 204 2-s2.0-0033843575 10.1006/clim.2000.4897
25. Klinman D. M., Tross D., Klaschik S., Shirota H., Sato T., Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Annals of the New York Academy of Sciences 2009 1175 80 88 2-s2.0-70349453647 10.1111/j.1749-6632.2009.04970.x
26. Shirota H., Gursel I., Gursel M., Klinman D. M., Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. Journal of Immunology 2005 174 8 4579 4583 2-s2.0-17044423406
27. Avalos A. M., Ploegh H. L., Competition by inhibitory oligonucleotides prevents binding of CpG to C-terminal TLR9. European Journal of Immunology 2011 41 10 2820 2827 10.1002/eji.201141563
28. Ashman R. F., Goeken J. A., Latz E., Lenert P., Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding. International Immunology 2011 23 3 203 214 2-s2.0-79952608158 10.1093/intimm/dxq473
29. Lenert P. S., Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for toll-like receptors (TLR) 7 and 9. Mediators of Inflammation 2010 2010 10 2-s2.0-77953532645 10.1155/2010/986596 986596
30. Boyd J. H., Toll-like receptors and opportunities for new sepsis therapeutics. Current Infectious Disease Reports 2012 14 5 455 461 10.1007/s11908-012-0273-5
31. Feng Y., Zou L., Zhang M., Li Y., Chen C., Chao W., MyD88 and Trif signaling play distinct roles in cardiac dysfunction and mortality during endotoxin shock and polymicrobial sepsis. Anesthesiology 2011 115 3 555 567 10.1097/ALN.0b013e31822a22f7
32. Annane P. D., Bellissant P. E., Cavaillon J. M., Septic shock. The Lancet 2005 365 9453 63 78 2-s2.0-11444249412 10.1016/S0140-6736(04)17667-8 (Pubitemid 40082148)
33. Bennett-Guerrero E., Grocott H. P., Levy J. H., Stierer K. A., Hogue C. W., Cheung A. T., Newman M. F., Carter A. A., Rossignol D. P., Collard C. D., A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesthesia and Analgesia 2007 104 2 378 383 2-s2.0-33846456617 10.1213/01.ane.0000253501.07183.2a (Pubitemid 46146745)